Special items: Ovarian Cancer and Us blog best viewed in Firefox

Monday, April 19, 2010

financial news: Abstracts Highlighting Sunesis' Phase 2 Voreloxin Data Accepted for Presentation at 2010 ASCO Meeting

The presentations include an oral presentation of final data from the Company's Phase 2 trial of voreloxin in ovarian cancer....

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.